Research programme: Alzheimer's disease therapeutic - BioibericaAlternative Names: PRJ 212
Latest Information Update: 20 Dec 2016
At a glance
- Originator Bioiberica
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 29 Nov 2016 Bioiberica plans a clinical trial for Alzheimer's disease in Spain (NCT02991235)
- 28 Jul 2016 Preclinical trials in Alzheimer's disease in Spain (PO)